Introduction {#sec0005}
============

Bovine respiratory disease (BRD) is one of the main health issues encountered in non-weaned beef calves, and can lead to high economic losses ([@bib0010], [@bib0230]). Viral infections generally initiate BRD and predispose animals to secondary bacterial infections ([@bib0130]). Bovine respiratory syncytial virus (BRSV), an *Orthopneumovirus* of the *Pneumoviridae* family, is a major virus involved in the BRD complex and is highly prevalent in both dairy and beef herds ([@bib0030], [@bib0155], [@bib0200]). Likewise, bovine parainfluenza-3 virus (bPI3V), a *Respirovirus* of the *Paramyxoviridae* family, is another virus involved in the BRD complex, widely prevalent in herds ([@bib0080]). Vaccines against BRSV and bPI3V are widely used to control BRD, especially in beef calves. In a French study of 165 cow-calf herds in 2000, 116/186 (62%) batches of beef calves were vaccinated against BRSV ([@bib0005]).

The neonatal period is a significant risk period for BRD. The immune system of newborn calves differs from that of adults in several respects ([@bib0040], [@bib0045]). Although functional at birth, the immune system of a calf remains immature until six months of age ([@bib0100], [@bib0195]), and the immune response during this time is weak, slow and more easily overcome by pathogenic microorganisms. In addition, maternally derived antibodies (MDA), which are transmitted through colostrum and remain present for up to six months, can interfere negatively with immunization of newborn calves after vaccination ([@bib0065], [@bib0115]). To overcome interference between parenteral vaccines and MDA, intranasal vaccination strategies using modified live vaccines for respiratory diseases have been developed and used widely for many years ([@bib0240]). Intranasal vaccination is able to induce protective immunity in newborn calves despite the presence of MDA by priming mucosal immunization of the upper respiratory tract whereas protective immunity is inconsistent after parenteral vaccinations ([@bib0140]).

Veterinary vaccine efficacy is mainly evaluated in challenge trials under controlled conditions ([@bib0120]). The efficacy of BRSV intranasal vaccines has been proven in many challenge trials under controlled conditions even when vaccinations are performed in the presence of MDA ([@bib0075], [@bib0140]). However, these studies generally do not consider variations that occur under field conditions, such as exposure to other pathogens, or host and environmental factors. Field trials are therefore needed to reliably evaluate vaccine effectiveness ([@bib0120]). To our knowledge, only one study dedicated to BRSV intranasal vaccination effectiveness has been carried out under field conditions in newborn dairy calves. In that study, no decrease in BRD incidence or lung lesions associated with pneumonia was demonstrated, but an increase in average daily gain was observed ([@bib0135]). It should be noted, however, that the management of dairy calves is quite different from that of beef suckler calves. Indeed, in cow-calf systems, animals of different susceptibilities to respiratory diseases or with different immune statuses are mixed in collective barns, whereas dairy calves are classically housed in individual pens during the first eight weeks of life before being sorted and mixed into groups of similar age in collective barns.

One BRSV-bPI3V intranasal vaccine authorized for use in newborn calves to prevent BRD has been available for over 10 years in Europe (Vaccine B, Rispoval RS + PI3 Intranasal, Zoetis). The efficacy and the safety of Vaccine B have been demonstrated in several experimental studies ([@bib0210], [@bib0205]). With this vaccine, nasal shedding of BRSV and bPI3V in vaccinated calves with or without MDA was reduced after challenges with BRSV and bPI3V respectively. Additionally, the severity of clinical disease was also reduced after BRSV in vaccinated calves with BRSV MDA. Moreover, this vaccine has been widely used in Europe and is now a benchmark for BRSV-bPI3V intranasal vaccines. Recently, several new BRSV intranasal vaccines have been launched in Europe. Our study aimed to compare the effectiveness of a new intranasal vaccine against BRSV and bPI3V (Vaccine A, Bovalto Respi Intranasal, Boehringer Ingelheim) with that of the benchmarked vaccine (Vaccine B) in terms of decreasing BRD morbidity in newborn beef calves reared in a cow-calf farming system. As these two vaccines were very similar in their composition (i.e. bivalent modified live vaccines against BRSV and bPI3V) and their indication for use (i.e. active immunization), a non-inferiority study was performed.

Materials and methods {#sec0010}
=====================

The trial was carried out under the agreement of the Ethics Committee for Clinical and Epidemiological Veterinary Research of Oniris (CERVO, Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering, France; Approval number, CERVO-2018-8-V; Approval date, 8 October, 2018).

Vaccines {#sec0015}
--------

Vaccines A and B contain BRSV and bPI3V strains administered as a single dose of 2 mL with an intranasal applicator. A dose of Vaccine A (evaluated vaccine) contains between 10^4.0^ and 10^6.0^ TCID~50~ of BRSV Bio 24/A strain and between 10^5.0^ and 10^7.5^ TCID~50~ of bPI3V strain Bio 23/A reconstituted with phosphate buffered saline. A dose of Vaccine B (benchmarked vaccine) contains between 10^5.0^ and 10^7.2^ 50% tissue culture infective doses (TCID~50~) of BRSV 375 strain and between 10^5.0^ and 10^8.6^ TCID~50~ of temperature-sensitive mutant bPI3V strain RLB 103 reconstituted with saline.

Study design {#sec0020}
------------

### Type of trial {#sec0025}

A randomized non-inferiority multicentre trial was carried out to assess whether Vaccine A was at least as effective as Vaccine B, with a pre-stated margin of non-inferiority (*δ*) for the prevention of BRD in newborn beef cattle. The null hypothesis (H~0~) was that Vaccine A was inferior to Vaccine B in preventing BRD, whereas the alternative hypothesis (H~a~) was that Vaccine A was not inferior by more than the predefined non-inferiority margin. The hypothesis statements may be summarized as follows:H~0~: (P~BRD~\[Vaccine A\] -- P~BRD~\[Vaccine B\]) ≥  *δ*H~a~: (P~BRD~\[Vaccine A\] -- P~BRD~\[Vaccine B\]) \<  *δ*

where P~BRD~ was the prevalence rate of calves treated for BRD during the study period and *δ* the non-inferiority margin.

### Determination of the non-inferiority margin {#sec0030}

Due to the lack of published field trials of the effectiveness of Vaccine B, it was not possible to determine the non-inferiority margin using a 2-step approach as described by [@bib0095]. However, efficacy and the safety of Vaccine B has been demonstrated in controlled challenge trials, and this vaccine has been until now been considered as the benchmarked BRSV-bPI3V IN vaccine. Thus, based on clinical judgment, because 5% was the largest loss of effectiveness of Vaccine A that would be considered clinically insignificant, the non-inferiority margin *δ* was defined as 5%.

### Sample size determination {#sec0035}

Sample size was determined using the package 'TrialSize' in R[1](#fn0005){ref-type="fn"} based on a non-inferiority trial with the prevalence of calves treated for BRD during the study period as the primary outcome. Four hundred and forty-six (446) calves per group were needed to demonstrate non-inferiority assuming *α*  = 0.05, *β*  = 0.20, *δ*  = 0.05 and a prevalence of BRD in the active control vaccine group B of 10%. As it was a stratified multicentre individually randomized trial with two equal group sizes (A/B) and an equal number of calves in the two groups on each farm, the inflating factor was defined as 1 −  *ρ*, with *ρ* the intraclass correlation coefficient ([@bib0215], [@bib0220]). After assigning this inflation factor with *ρ*  = 0.14 ([@bib0105]) and assuming 20% of loss to follow-up, it was decided to enroll at least 920 calves in the study.

Animals {#sec0040}
-------

### Herd selection {#sec0045}

Forty cow-calf farms with 110 ± 55 calvings (mean ± standard deviation, SD), located in four areas of France (Auvergne-Rhône-Alpes, Bretagne, Nouvelle-Aquitaine, Pays de La Loire), were selected for this study. Initial herd selection by veterinarians was based on the following criteria: (1) pure Charolais breed herds, (2) at least 30 calvings between December 2018 and April 2019, (3) calvings in stalls and a housing period as long as possible, ideally at least three months after vaccination, (4) ability to detect and treat sick animals and to record health events, and (5) no other BRD vaccination program during the study period (from birth to 3 months after enrolment). Herds were then enrolled in the study after farmers agreed to participate.

### Calf selection {#sec0050}

On each farm, 1 to 3 blocks of 10 calves were enrolled (3, 6 and 32 farms had respectively 1, 2 or 3 blocks). As soon as there were more than 10 calves over 10 days of age, a clinical examination of each calf was performed by a veterinarian. Only calves in good health (no intercurrent illness detected during the clinical examination) at the time of enrolment were included. If a calf had been ill and treated for BRD or other diseases before the day of inclusion, enrolment was possible only after full clinical recovery of the animal.

Randomization and vaccination protocols {#sec0055}
---------------------------------------

Randomization was performed with a 1:1 allocation ratio. In each block of 10 enrolled calves from each farm, calves were sorted by decreasing age. A predefined randomized spreadsheet was prepared for each block: a random drawing was performed using the Rand function of MS Excel to assign the vaccine to the oldest calf, then the following calves were vaccinated alternately with one of the two vaccines.

Vaccines were administered by one veterinary investigator with calves restrained by the farmer, while another veterinary investigator reconstituted vaccines and recorded data. The vaccines were administered according to the manufacturer\'s recommendations: for Vaccine A, 1 mL in each nostril with the specific intranasal applicator (cannula and disk) provided by the manufacturer; for Vaccine B, 2 mL in one nostril with the specific intranasal applicator (cannula) provided by the manufacturer.

Intranasal applicators were changed between each calf. Due to the different administration modalities for the two vaccines, it was not possible to carry out a blinded vaccination. However, data were collected and registered by another veterinary investigator who kept randomization sheets and was not involved in the monitoring of calves after vaccination. To avoid potential bias in later husbandry, farmers were asked to not read the tag numbers of calves during vaccination. After vaccination, cow-calf couples were raised in the same pen according to the usual rearing conditions on each farm.

Outcomes and data collection {#sec0060}
----------------------------

The protocol started with vaccination and ended three months later. The primary outcome for analysis was BRD events, defined by at least one respiratory sign (such as cough, dyspnea, and/or nasal discharge) associated with at least one general clinical sign (hyperthermia, depression, and/or anorexia). Secondary outcomes included the time between vaccine administration and the occurrence of BRD, calf mortality, and the number of calves treated with antibiotics or anti-inflammatory drugs during the study.

For each calf, demographic data (tag number, date of birth, sex, and parity of the dam) were extracted from the official identification databases, and medical history was gathered from animal health records of the farm. For three months following vaccination, the farmers, under supervision of the veterinary investigators, had to monitor and record all observations and treatments carried out: date, clinical signs, diagnosis (respiratory disorders and others) and drug administration (antibiotic and/or anti-inflammatory preparations).

In the event of mortalities during the study, a veterinary investigator performed required necropsy examinations to identify the cause of death. In the case of bronchopneumonia, lung samples (approximately 5 cm^3^) were frozen at −20 °C for PCR analysis. Multiplex real-time PCR assays (Pack Respiratory 8 Bio-T kit, Biosellal) designed for the detection of eight BRD agents (BRSV, bPI3V, bovine Coronavirus, Influenza D, *Mannheimia haemolytica*, *Pasteurella multocida*, *Mycoplasma bovis*, *Histophilus somni*) were performed in Agrivalys 71.

Post-admission exclusion {#sec0065}
------------------------

Calves with incomplete data, vaccinated before 10 days or after 60 days of age, or treated for BRD without at least two clinical signs being recorded, or as part of a metaphylaxis protocol, or vaccinated after the beginning of the grazing period were excluded.

Statistical analysis {#sec0070}
--------------------

The characteristics of calves assigned to the two vaccine groups were compared to assess homogeneity: Student\'s *t*-test was used for continuous variables (i.e., *age at vaccination*, *risk period*) after checking normality, and chi-squared or Fisher tests were used for categorical variables (i.e., *parity of dam*, *sex*, and *disease occurrence before vaccination*).

The statistical analysis of the primary outcome was performed using a mixed logistic regression model (with '*calf*' as the statistical unit). The primary explanatory variable of interest was *vaccine*. Other variables were also tested (*sex*, *parity of dam*, *age at vaccination*, *risk period*) and kept in the model if *P*  \< 0.2 in the univariable analysis. A backward stepwise elimination of variables was then performed until all explanatory variables with *P*  \< 0.05 were included in the final model, taking into account potential confounders. *Herd* (categorical variable) was included as a random effect. The variable *risk period* was kept in the model to adjust BRD occurrence to the variation of the duration of exposition to pathogens between calves. The variables *vaccine* and *risk period* were forced in the final model, written as:$$BRD_{ij} \sim Bernoulli(p_{ij})$$ $$Logit(p_{ij}) = \ln\left( \frac{p_{ij}}{1 - p_{ij}} \right) = \beta_{0} + vaccine_{ij}\beta_{1} + risk\, period_{ij}\beta_{2} + X_{ij}\beta_{k} + v_{j}$$ $$v_{j} \sim Normal(0,\sigma_{v}^{2})$$

where *BRD* ~*ij*~ is the occurrence of a BRD case diagnosed during the study *Risk Period* for the calf *i* of the herd *j* with a probability of occurrence *p* ~*ij*~, $\beta_{0}$ is the intercept, *vaccine* ~*ij*~ is either Vaccine A or B, *risk period* ~*ij*~ is the duration of the in-house risk period, *X* ~*ij*~ is *sex*, *parity of dam* and *age at vaccination* variables and *v* ~*j*~ is the random effect for herd *j*. Herd random effect followed a normal distribution with mean 0 and variance $\sigma_{v}^{2}$.

The difference in BRD prevalence between vaccine groups and its 95% confidence interval (CI) was calculated from the model. Non-inferiority of Vaccine A compared with Vaccine B was concluded if the upper bound of the 2-sided 95% CI of the difference of BRD prevalence between the two vaccines was smaller than the non-inferiority margin *δ* ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Four possible scenarios of a non-inferiority trial comparing Vaccine A to Vaccine B for preventing BRD. The margin of non-inferiority (*δ*) is drawn by a vertical dashed line. P~BRD~ is the prevalence of BRD cases diagnosed during the study risk period of housing after vaccination. Error bars indicate 2-sided 95% confidence interval (CI) of the difference in BRD incidence ([@bib0145]). S: if the CI lies wholly to the left of zero, Vaccine A is superior. NI: if the CI lies to the left of *δ* and includes zero, Vaccine A is non-inferior. IC: if the CI includes *δ* and zero, the difference is non-significant but the result regarding non-inferiority is inconclusive. I: if the CI is wholly above *δ*, Vaccine A is inferior. VT is the representation of the main outcome of this non-inferiority trial. The black block indicates the difference in BRD incidence between Vaccine A group and Vaccine B group. Non-inferiority of Vaccine A compared to Vaccine B at a margin of 5% is demonstrated because the 95% CI lies to the left of *δ* (=5%) and includes zero.Fig. 1

Secondary outcomes were compared between the two vaccine groups using the chi-squared test, Fisher test or Student\'s *t*-test. All analyses were carried out using R software^1^ and a statistical significance at *P*  ≤ 0.05 was used.

Results {#sec0075}
=======

Descriptive results {#sec0080}
-------------------

A total of 1120 calves from 40 farms were enrolled in the study. Data from 185 calves were excluded: 40 because of incomplete data, 85 for date of vaccination before 10 days or after 60 days of age, 30 for being treated for BRD without at least two clinical signs or in a metaphylaxis protocol, and 30 for being vaccinated after the beginning of the grazing period (no housing period). Thus, a total of 935 calves from 39 herds were used in the study analysis: 24 ± 7 calves (mean ± SD) per herd. The two experimental groups were homogeneous in regard to age at vaccination, duration of in-house risk period, parity of dams, sex ratio, and occurrence of diseases before vaccination ([Table 1](#tbl0005){ref-type="table"} ).Table 1Calf characteristics in vaccine groups A and B.Table 1VariableVaccine group (*n* = 935)*P*A (*n* = 468)B (*n* = 467)Age at vaccination in days (mean ± SD)25.97 ± 11.6225.85 ± 11.540.88Duration of in-house risk period in days (mean ± SD)56.52 ± 28.2557.00 ± 27.930.80Parity 1 (*n* = 279)1431360.51 2 (*n* = 157)7285 3 and more (*n* = 499)253246Sex Male (*n* = 447)2352120.14 Female (*n* = 488)233255Occurrence of diseases before vaccination No disease (*n* = 873)4374361 Respiratory (*n* = 6)33 Other than respiratory [a](#tblfn0005){ref-type="table-fn"} (*n* = 56)2828[^1][^2]

Primary outcome {#sec0085}
---------------

The occurrence of BRD during the in-house risk period between the two vaccine groups was similar ([Table 2](#tbl0010){ref-type="table"} ). Using least squares means of model outcome (BRD events), the difference P~BRD~(Vaccine A) − P~BRD~(Vaccine B) was estimated at −0.4% with a 95% CI between −1.6% and 0.8%. Non-inferiority of Vaccine A compared to Vaccine B was concluded since the upper limit of the 2-sided 95% CI (0.8%) of the difference in prevalence of calves diagnosed with BRD between the two vaccines was smaller than *δ* ([Fig. 1](#fig0005){ref-type="fig"}). BRD incidence in our study was 0.74 cases per 1000 calf-days at risk ([Table 3](#tbl0015){ref-type="table"} ).Table 2Multivariable results of mixed logistic regression model of bovine respiratory disease (BRD) prevalence after intranasal vaccination of non-weaned beef calves.Table 2VariableCategoryNumber of calves evaluatedOdds ratio of BRD occurrence95% Confidence interval*P*[a](#tblfn0010){ref-type="table-fn"}VaccineVaccine B467ReferenceVaccine A4680.610.30--1.250.17Duration of in-house risk period in days(0--45)313Reference(45--67.5)2438.881.07--73.660.04(67.5--90)3796.610.86--50.990.07[^3]Table 3Incidence of bovine respiratory disease cases in the two vaccine groups.Table 3Vaccine groupNumber ofIncidence rate[a](#tblfn0015){ref-type="table-fn"}Calf-days at riskCasesVaccine A25,538150.59Vaccine B26,031230.88Total51,569380.74[^4]

Secondary outcome {#sec0090}
-----------------

The two experimental groups were similar in regard to time between vaccination and occurrence of BRD, treatments and mortality ([Table 4](#tbl0020){ref-type="table"} ). For the six calves which died during the study period, BRSV was not detected from the samples collected during the necropsy procedure ([Table 5](#tbl0025){ref-type="table"} ).Table 4Comparisons of secondary outcomes between the two vaccine groups.Table 4OutcomeVaccine group (*n* = 935)*P*A (*n* = 468)B (*n* = 467)Calves treated for BRD with Antibiotics (%)15 (3.2)23 (4.9)0.23 Non-steroidal anti-inflammatories (%)12 (2.6)17 (3.6)0.34 Steroidal anti-inflammatories (%)1 (0.2)2 (0.4)0.50Mortalities (%)1 (0.2)5 (1.1)0.11Time between vaccination and occurrence of BRD in days (mean ± SD)33 ± 2028 ± 220.45[^5]Table 5Results of multiplex real-time PCR on lung samples for detection of eight respiratory pathogens from necropsies of dead calves.Table 5Calf numberVaccine groupHerd numberPathogen detected in multiplex real-time PCR[a](#tblfn0020){ref-type="table-fn"}BRSVbPI3VMhPmMbHsbCoID14B1No sample244B13No sample913B37−+++−+−−941A38−−−+−++−955B38−−−+−−+−967B38−+−+−−−−[^6][^7]

Discussion {#sec0095}
==========

The objective of this study was to compare the effectiveness of the newly available BRSV-bPI3V intranasal vaccine to the benchmarked vaccine under field conditions in newborn beef calves reared in a cow-calf system. Based on our results, non-inferiority of Vaccine A compared to Vaccine B was concluded. Due to the lack of studies dedicated to the effectiveness of Vaccine B compared to a placebo, the non-inferiority margin *δ* was defined as 5% only, based on a clinical judgment. This margin is narrow compared to the one used in most vaccine trials, with *δ* usually fixed at 10% as reviewed by [@bib0050]. Choosing a more conservative non-inferiority margin required an increased sample size and improved the clinical significance of the trial. Indeed, based on the experiences of the authors, an increase of more than 5% of BRD events (i.e., the primary outcome) in the Vaccine A group compared to the Vaccine B group was considered unfavorable.

In this study, calves from the two vaccine groups were mixed together in order to homogenize as much as possible environmental conditions and exposure to pathogens. This design is often chosen in field studies dealing with vaccine effectiveness ([@bib0160], [@bib0175], [@bib0235]). Moreover, in a cow-calf system, this design enables the absence of separation of paired calves of the two vaccine groups after randomization, and improves blind assessment of calf health in a single group. However, a bias in vaccine effectiveness evaluation could be introduced with this method. The reduction of virus shedding after vaccination of the calves of one vaccine group contributes to the protection of the calves of the other vaccine group reared in the same environment ([@bib0165], [@bib0170], [@bib0180]). Indeed, apparent effectiveness of the test vaccine could be improved if the comparison involved a reference vaccine with a better shedding reduction efficacy. Moreover, Vaccines A and B are both modified live vaccines. Cross-immunization thus could occur between the two vaccine groups. In previous studies using commercial vaccines including the reference vaccine, nasal shedding of vaccine-origin viruses was detected by PCR in nasal swabs during 14 days in most of the vaccinated calves after vaccination and was detected up to 28 days post vaccination in a few calves ([@bib0190], [@bib0225]).

The study was designed to determine the effectiveness of two commercial vaccines under conditions as close as possible to those encountered by calves reared in beef herds. Although the minimum age at vaccination recommended by the manufacturers is 9 and 10 days of age for Vaccines B and A, respectively, under our conditions the mean age (±SD) at vaccination was 26 ± 12 days. This delay in administrating vaccines was due to the distribution of births on each farm and the packaging of the vaccines in 5-dose bottles. Since both vaccines are available in a 5-dose bottle, 10 calves had to be over 10 days of age before being vaccinated in order to randomize them into two equal groups of five calves. However, this difference between the recommended and actual age at vaccination was the same in both groups and is common in French cow-calf systems.

Most of the efficacy studies for BRSV and bPI3V intranasal vaccination include a controlled challenge, but challenges may not reproduce natural exposure under variable host and environmental factors ([@bib0120]). It has been observed that many BRSV infection models failed to reproduce the severe clinical signs of the disease, complicating the evaluation of vaccine efficacy ([@bib0020], [@bib0025], [@bib0185]). In these studies, efficacy was demonstrated in newborn calves both in the absence of BRSV-specific MDAs ([@bib0070], [@bib0205]) and in their presence ([@bib0090], [@bib0110]). However, the absence of maternal antibody interference is not always observed ([@bib0085]). In our study, colostral immunity in calves was not systematically controlled for practical reasons, and the BRSV and bPI3V serological status of calves at the time of vaccination was unknown. Due to the high prevalence of BRSV in France, most of the vaccinations were likely to have been performed in the presence of BRSV-specific MDAs.

As observed in a previous study, BRSV and bPI3V infections were found in 71% and 80% of cow-calf farms respectively ([@bib0015]). Furthermore, challenge trials do not reproduce the variability of host and environmental conditions that may be encountered in the field, such as variable passive immune transfer ([@bib0150]), variable calf housing ([@bib0005], [@bib0055], [@bib0125]) and variable seasonal or weather conditions ([@bib0035], [@bib0060]). For these reasons, a multicentre study was chosen in order to reproduce this variability of environmental factors. Both efficacy assessment in experimental challenges and effectiveness assessment in field trials have limits but are complementary.

Contrary to challenge trials, the exposure of calves to pathogens, in particular to BRSV and bPI3V, is rarely controlled in a field study ([@bib0075], [@bib0135]). The authors acknowledge that monitoring BRSV and bPI3V exposure (by means such as PCR or virus isolation on deep nasal swabs or fluid of transtracheal aspiration or bronchoalveolar lavage, or serology on sentinels) would have allowed us to assess specifically the effectiveness of vaccines against BRSV and bPI3V, and not only the prevention of BRD. As previously reported, monitoring exposure to pathogens in a vaccinated population is very difficult for both practical and economic reasons ([@bib0075]). Indeed, the short viremia would require repeated samplings of a large population. In a recent field trial evaluating BRSV and bPI3V intranasal vaccination in dairy calves, [@bib0135] similarly did not assess the exposure of calves to BRSV and bPI3V, and monitored BRD morbidity alone.

However, the exposure of calves to respiratory pathogens in our study can be attested by the measurement of BRD incidence, which was 0.74 cases per 1000 calf-days at risk. Although this BRD incidence was low, it remains consistent with the incidence observed in another French study in a comparable breeding system in which respiratory vaccination was inconsistent: 1.89 cases per 1000 calf-days at risk in 137 farms ([@bib0010]). Circulation of respiratory pathogens in the study farms can also be attested by the viruses (bPI3V, bovine Coronavirus) and bacteria (*Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*) identified at necropsy in dead animals. To overcome the variability in the exposure to pathogens under field conditions, our study would need to be repeated.

Conclusions {#sec0100}
===========

The effectiveness of a newly available commercial BRSV-bPI3V intranasal vaccine to control BRD has been demonstrated under field conditions. To the authors' knowledge, this is the first study under field conditions assessing BRSV and bPI3V intranasal vaccination effectiveness in newborn beef calves in a cow-calf system. Data from challenge studies or from dairy calf field studies cannot be extrapolated to beef calves. Beef cattle from different age groups with different immune statuses against respiratory pathogens are mixed together in a specific in-house environment, in contrast to dairy calves which are typically housed in individual pens or in collective pens with animals of the same age.
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[^1]: SD, Standard deviation.

[^2]: All neonatal diseases were diagnosed and treated (i.e., septicaemia, diarrhea, umbilical infection, others).

[^3]: For each variable, refers to level of significance between the category under consideration and the reference category.

[^4]: Per 1000 calf-days at risk.

[^5]: BRD, Bovine respiratory disease; SD, standard deviation.

[^6]: BRSV, Bovine respiratory syncytial virus; bPI3V, bovine Parainfluenza Virus type 3; Mh, *Mannheimia haemolytica*; Pm, *Pasteurella multocida*; Mb, *Mycoplasma bovis*; Hs, *Histophilus somni*; bCo, bovine Coronavirus; ID, Influenza D virus.

[^7]: Pack Respiratory 8 Bio-T kit, Biosellal.
